A comprehensive study evaluating germline <scp><i>FANCG</i></scp> variants in predisposition to breast and ovarian cancer
Our study suggests that heterozygous germline FANCG variants are unlikely to contribute to the development of BC or OC.
Authors
- Zdeňka Vlčková
- Václava Curtisová (ORCID: https://orcid.org/0000-0001-7829-2881)
- Tomáš Zima (ORCID: https://orcid.org/0000-0001-8518-6972)
- Zdeněk Kleibl (ORCID: https://orcid.org/0000-0003-2050-9667)
- Marta Kalousová (ORCID: https://orcid.org/0000-0001-5928-3074)
- Jana Soukupová (ORCID: https://orcid.org/0000-0003-2413-1542)
- Markéta Janatová (ORCID: https://orcid.org/0000-0003-2816-6769)
- Viktor Stránecký (ORCID: https://orcid.org/0000-0002-2599-6479)
- Milena Hovhannisyan
- Petr Nehasil (ORCID: https://orcid.org/0000-0002-7920-1117)
- Klára Horáčková (ORCID: https://orcid.org/0000-0002-7390-4751)
- Kateřina Matějková
- Monika Koudová (ORCID: https://orcid.org/0000-0002-1323-4936)
- Barbora Šťastná
- Štěpán Chvojka
- Ondřej Scheinost
- Vera Krutilkova
- Matous Palek (ORCID: https://orcid.org/0000-0001-6823-0089)
- Petra Kleiblová (ORCID: https://orcid.org/0000-0002-4806-9854)
- Marcela Kosařová
- Lenka Foretová (ORCID: https://orcid.org/0000-0003-0494-2620)
- Petra Zemánková (ORCID: https://orcid.org/0000-0001-7315-1975)
- J. Hojný (ORCID: https://orcid.org/0000-0002-3563-2484)
- Sandra Jelínková (ORCID: https://orcid.org/0000-0003-3993-4831)
- Libor Macůrek (ORCID: https://orcid.org/0000-0002-0987-1238)
- Jan Král (ORCID: https://orcid.org/0000-0002-3877-1033)
- Ondřej Havránek (ORCID: https://orcid.org/0000-0001-5826-3557)
- Michaela Krausová
- Marta Černá
- Leona Cerna
- Lucie Hrušková (ORCID: https://orcid.org/0000-0002-4857-2388)
- Marianna Borecká (ORCID: https://orcid.org/0000-0001-6413-222X)
- Ivan Šubrt (ORCID: https://orcid.org/0000-0003-2540-0863)
- Lenka Stolařová (ORCID: https://orcid.org/0000-0002-0047-1502)
- Mária Janíková (ORCID: https://orcid.org/0000-0002-2752-5857)
- Spiros Tavandzis (ORCID: https://orcid.org/0000-0001-9845-2408)
- Michal Vočka (ORCID: https://orcid.org/0000-0002-9386-657X)
- Pavel Just (ORCID: https://orcid.org/0000-0003-1983-6310)
- Markéta Šafaříková (ORCID: https://orcid.org/0000-0003-2896-2108)
- Eva Macháčková (ORCID: https://orcid.org/0000-0002-0246-1471)
- Drahomíra Springer (ORCID: https://orcid.org/0000-0003-4756-0585)
- Petra Duskova
- Renáta Michalovská
- Taťána Doležalová
- Pavel Pesek
- Eva Tureckova
- Jan Novotný (ORCID: https://orcid.org/0000-0001-6021-0577)
- Monika Černá
- Kamila Vesela
- Barbora Němcová (ORCID: https://orcid.org/0009-0005-4873-7698)
- Madiha Kanwal
Institutions
- Charles University (CZ)
- University Hospital Olomouc (CZ)
- Masaryk Memorial Cancer Institute (CZ)
- Nemocnice České Budějovice (CZ)
- Institute of Clinical and Experimental Medicine (CZ)
- Czech Academy of Sciences, Institute of Molecular Genetics (CZ)
- General University Hospital in Prague (CZ)
- Palacký University Olomouc (CZ)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1002/cam4.70103
- Citations
- 4
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- Univerzita Karlova v Praze
- Grantová Agentura, Univerzita Karlova
- Ministerstvo Školství, Mládeže a Tělovýchovy
- Ministerstvo Zdravotnictví Ceské Republiky